Sanofi-Synthelabo India, a part of pharma major Sanofi group, will invest Rs 90 crore in ASCL through a combination of primary and secondary funding
Sanofi-Synthelabo India, a part of pharma major Sanofigroup, will invest Rs 90 crore in ASCL through a combination of primary and secondary funding.
Through this investment, both Apollo and Sanofi would endeavour to expand Apollo Sugar Clinics to provide superior value to patients and doctors with an enhanced geographic reach, and provide high quality outcome oriented set of services.
Dr Prathap Reddy, chairman and founder, Apollo Hospitals Group, said, “I am confident that with this investment, Apollo Sugar Clinics is even better positioned to offer patients advanced care and counselling for diabetes management. I am delighted to be partnering with Sanofi, a global leader in diabetes management.” Business Standard
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…